Uptravi (selexipag) is now available with public funding for pulmonary arterial hypertension (PAH) patients in Canada living in nine…
Articles by Alice Melão, MSc
PhaseBio Pharmaceuticals started dosing its investigational compound PB1046 in patients with pulmonary arterial hypertension (PAH) in a Phase 2b…
INOpulse is advancing in a number of clinical trials as a potential treatment of pulmonary hypertension (PH) associated with…
Treatment with inhaled Ventavis (iloprost) has limited effectiveness in improving the survival rate of patients with pulmonary arterial hypertension…
Patients with systemic sclerosis (SSc) at risk of having pulmonary hypertension (PH) also have similar risk factors for a poorer…
Long-term use of ralinepag, an investigational therapy being developed by Arena Pharmaceuticals, can promote positive changes in the outcome of…
Drinking nitrate-rich beetroot juice can improve the production of nitric oxide in patients with pulmonary arterial hypertension (PAH), a…
Long-term oxygen therapy had a damaging effect on rats with induced idiopathic pulmonary arterial hypertension (PAH), leading to poorer outcomes and…
A protein called RAGE was found to be an important contributor to the remodeling of blood vessels in pulmonary arterial…
Pregnancy among women with heart diseases is generally safe, with just a few deaths being reported in the ROPAC…
Actelion Pharmaceuticals has filed a request with the European Medicines Agency for the expanded approval of Opsumit (macitentan)…
Evaluation of Midkine (MDK) and Follistatin-like 3 (FSTL3) protein levels in the blood can help identify patients with systemic…